Overview

One Year Drug Treatment in First-Episode Schizophrenia

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.
Phase:
Phase 4
Details
Lead Sponsor:
Heinrich-Heine University, Duesseldorf
Collaborators:
German Federal Ministry of Education and Research
German Research Network On Schizophrenia
Humboldt-Universität zu Berlin
Janssen-Cilag Ltd.
Mainz University
Martin-Luther-Universität Halle-Wittenberg
RWTH Aachen University
Universität Duisburg-Essen
University Hospital Tuebingen
University of Bonn
University of Cologne
University of Göttingen
University of Jena
University of Mannheim
University of München
University of Wuerzburg
Treatments:
Haloperidol
Haloperidol decanoate
Risperidone